LRRK2 Facilitates tau Phosphorylation through Strong Interaction with tau and cdk5

Biochemistry

Volumn 54, Issue 33, 2015, Pages 5198-5208

  Shanley, Mary R ^a   Hawley, Dillon ^a   Leung, Shirley ^a   Zaidi, Nikhat F ^a   Dave, Roshni ^a   Schlosser, Kate A ^b   Bandopadhyay, Rina ^c   Gerber, Scott A ^b   Liu, Min ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BINDING ENERGY; BRAIN; ENZYMES; PHOSPHORYLATION; PROTEINS; RECOMBINANT PROTEINS;

HYPERPHOSPHORYLATED; KINASE ACTIVITY; LEUCINE-RICH REPEATS; SCAFFOLD PROTEIN; SH SY5Y CELLS; SPECIFIC ACTIVITY; STRONG BINDING; STRONG INTERACTION;

SCAFFOLDS (BIOLOGY);

CYCLIN DEPENDENT KINASE 5; LEUCINE RICH REPEAT KINASE 2; MUTANT PROTEIN; RECOMBINANT PROTEIN; SERINE; SMALL INTERFERING RNA; TAU PROTEIN; TUBULIN; LRRK2 PROTEIN, HUMAN; LRRK2 PROTEIN, MOUSE; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; BIOCATALYSIS; BRAIN; CHEMISTRY; GENETICS; KINETICS; METABOLISM; MOLECULAR GENETICS; MONONUCLEAR CELL; MUTATION; PHOSPHORYLATION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BIOCATALYSIS; BRAIN; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 5; HUMANS; KINETICS; LEUKOCYTES, MONONUCLEAR; MICE; MOLECULAR SEQUENCE DATA; MUTATION; PARKINSON DISEASE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; TAU PROTEINS; TUBULIN;

EID: 84939609978     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/acs.biochem.5b00326     Document Type: Article

References (51)

1. Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., Johnson, J., Martinez, J. R., Nicholl, D., Carrera, I. M., Pena, A. S., de Silva, R., Lees, A., Marti-Masso, J. F., Perez-Tur, J., Wood, N. W., and Singleton, A. B. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson?s disease Neuron 44, 595-600 10.1016/j.neuron.2004.10.023
2. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., Stoessl, A. J., Pfeiffer, R. F., Patenge, N., Carbajal, I. C., Vieregge, P., Asmus, F., Muller-Myhsok, B., Dickson, D. W., Meitinger, T., Strom, T. M., Wszolek, Z. K., and Gasser, T. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology Neuron 44, 601-607 10.1016/j.neuron.2004.11.005
3. Berg, D., Schweitzer, K. J., Leitner, P., Zimprich, A., Lichtner, P., Belcredi, P., Brussel, T., Schulte, C., Maass, S., Nagele, T., Wszolek, Z. K., and Gasser, T. (2005) Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson?s disease Brain 128, 3000-3011 10.1093/brain/awh666
4. Khan, N. L., Jain, S., Lynch, J. M., Pavese, N., Abou-Sleiman, P., Holton, J. L., Healy, D. G., Gilks, W. P., Sweeney, M. G., Ganguly, M., Gibbons, V., Gandhi, S., Vaughan, J., Eunson, L. H., Katzenschlager, R., Gayton, J., Lennox, G., Revesz, T., Nicholl, D., Bhatia, K. P., Quinn, N., Brooks, D., Lees, A. J., Davis, M. B., Piccini, P., Singleton, A. B., and Wood, N. W. (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson?s disease: clinical, pathological, olfactory and functional imaging and genetic data Brain 128, 2786-2796 10.1093/brain/awh667
5. Mata, I. F., Kachergus, J. M., Taylor, J. P., Lincoln, S., Aasly, J., Lynch, T., Hulihan, M. M., Cobb, S. A., Wu, R. M., Lu, C. S., Lahoz, C., Wszolek, Z. K., and Farrer, M. J. (2005) Lrrk2 pathogenic substitutions in Parkinson?s disease Neurogenetics 6, 171-177 10.1007/s10048-005-0005-1
6. Smith, W. W., Pei, Z., Jiang, H., Dawson, V. L., Dawson, T. M., and Ross, C. A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity Nat. Neurosci. 9, 1231-1233 10.1038/nn1776
7. West, A. B., Moore, D. J., Choi, C., Andrabi, S. A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K. L., Dawson, V. L., and Dawson, T. M. (2006) Parkinson?s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity Hum. Mol. Genet. 16, 223-232 10.1093/hmg/ddl471
8. Smith, W. W., Pei, Z., Jiang, H., Moore, D. J., Liang, Y., West, A. B., Dawson, V. L., Dawson, T. M., and Ross, C. A. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration Proc. Natl. Acad. Sci. U. S. A. 102, 18676-18681 10.1073/pnas.0508052102
9. Ujiie, S., Hatano, T., Kubo, S., Imai, S., Sato, S., Uchihara, T., Yagishita, S., Hasegawa, K., Kowa, H., Sakai, F., and Hattori, N. (2012) LRRK2 I2020T mutation is associated with tau pathology Parkinsonism Relat Disord 18, 819-823 10.1016/j.parkreldis.2012.03.024
10. Covy, J. P., Yuan, W., Waxman, E. A., Hurtig, H. I., Van Deerlin, V. M., and Giasson, B. I. (2009) Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations Mov. Disord. 24, 32-39 10.1002/mds.22096
11. Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., Tomiyama, H., Nakashima, K., Hasegawa, K., Obata, F., Yoshikawa, T., Kawakami, H., Sakoda, S., Yamamoto, M., Hattori, N., Murata, M., Nakamura, Y., and Toda, T. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson?s disease Nat. Genet. 41, 1303-1307 10.1038/ng.485
12. Simon-Sanchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., Kruger, R., Federoff, M., Klein, C., Goate, A., Perlmutter, J., Bonin, M., Nalls, M. A., Illig, T., Gieger, C., Houlden, H., Steffens, M., Okun, M. S., Racette, B. A., Cookson, M. R., Foote, K. D., Fernandez, H. H., Traynor, B. J., Schreiber, S., Arepalli, S., Zonozi, R., Gwinn, K., van der Brug, M., Lopez, G., Chanock, S. J., Schatzkin, A., Park, Y., Hollenbeck, A., Gao, J., Huang, X., Wood, N. W., Lorenz, D., Deuschl, G., Chen, H., Riess, O., Hardy, J. A., Singleton, A. B., and Gasser, T. (2009) Genome-wide association study reveals genetic risk underlying Parkinson?s disease Nat. Genet. 41, 1308-1312 10.1038/ng.487
13. Li, X., Patel, J. C., Wang, J., Avshalumov, M. V., Nicholson, C., Buxbaum, J. D., Elder, G. A., Rice, M. E., and Yue, Z. (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson?s disease mutation G2019S J. Neurosci. 30, 1788-1797 10.1523/JNEUROSCI.5604-09.2010
14. Melrose, H. L., Dachsel, J. C., Behrouz, B., Lincoln, S. J., Yue, M., Hinkle, K. M., Kent, C. B., Korvatska, E., Taylor, J. P., Witten, L., Liang, Y. Q., Beevers, J. E., Boules, M., Dugger, B. N., Serna, V. A., Gaukhman, A., Yu, X., Castanedes-Casey, M., Braithwaite, A. T., Ogholikhan, S., Yu, N., Bass, D., Tyndall, G., Schellenberg, G. D., Dickson, D. W., Janus, C., and Farrer, M. J. (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice Neurobiol. Dis. 40, 503-517 10.1016/j.nbd.2010.07.010
15. Li, Y., Liu, W., Oo, T. F., Wang, L., Tang, Y., Jackson-Lewis, V., Zhou, C., Geghman, K., Bogdanov, M., Przedborski, S., Beal, M. F., Burke, R. E., and Li, C. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson?s disease Nat. Neurosci. 12, 826-828 10.1038/nn.2349
16. Gillardon, F. (2009) Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability - a point of convergence in parkinsonian neurodegeneration? J. Neurochem. 110, 1514-1522 10.1111/j.1471-4159.2009.06235.x
17. Kawakami, F., Yabata, T., Ohta, E., Maekawa, T., Shimada, N., Suzuki, M., Maruyama, H., Ichikawa, T., and Obata, F. (2012) LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth PLoS One 7, e30834 10.1371/journal.pone.0030834
18. Bailey, R. M., Covy, J. P., Melrose, H. L., Rousseau, L., Watkinson, R., Knight, J., Miles, S., Farrer, M. J., Dickson, D. W., Giasson, B. I., and Lewis, J. (2013) LRRK2 phosphorylates novel tau epitopes and promotes tauopathy Acta Neuropathol. 126, 809-827 10.1007/s00401-013-1188-4
19. Baumann, K., Mandelkow, E. M., Biernat, J., Piwnica-Worms, H., and Mandelkow, E. (1993) Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5 FEBS Lett. 336, 417-424 10.1016/0014-5793(93)80849-P
20. Ahlijanian, M. K., Barrezueta, N. X., Williams, R. D., Jakowski, A., Kowsz, K. P., McCarthy, S., Coskran, T., Carlo, A., Seymour, P. A., Burkhardt, J. E., Nelson, R. B., and McNeish, J. D. (2000) Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5 Proc. Natl. Acad. Sci. U. S. A. 97, 2910-2915 10.1073/pnas.040577797
21. Ahn, J. S., Musacchio, A., Mapelli, M., Ni, J., Scinto, L., Stein, R., Kosik, K. S., and Yeh, L. A. (2004) Development of an assay to screen for inhibitors of tau phosphorylation by cdk5 J. Biomol. Screening 9, 122-131 10.1177/1087057103260594
22. Kettenbach, A. N., Schweppe, D. K., Faherty, B. K., Pechenick, D., Pletnev, A. A., and Gerber, S. A. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-like kinase activities in mitotic cells Sci. Signaling 4, rs5 10.1126/scisignal.2001497
23. Faherty, B. K. and Gerber, S. A. (2010) MacroSEQUEST: efficient candidate-centric searching and high-resolution correlation analysis for large-scale proteomics data sets Anal. Chem. 82, 6821-6829 10.1021/ac100783x
24. Milloy, J. A., Faherty, B. K., and Gerber, S. A. (2012) Tempest: GPU-CPU computing for high-throughput database spectral matching J. Proteome Res. 11, 3581-3591 10.1021/pr300338p
25. Taus, T., Kocher, T., Pichler, P., Paschke, C., Schmidt, A., Henrich, C., and Mechtler, K. (2011) Universal and confident phosphorylation site localization using phosphoRS J. Proteome Res. 10, 5354-5362 10.1021/pr200611n
26. Elias, J. E. and Gygi, S. P. (2007) Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry Nat. Methods 4, 207-214 10.1038/nmeth1019
27. Segel, I. H. (1975) Enzyme Kinetics, John Wiley & Sons, Inc, New York.
28. Liu, M., Dobson, B., Glicksman, M. A., Yue, Z., and Stein, R. L. (2010) Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities Biochemistry 49, 2008-2017 10.1021/bi901851y
29. Liu, M., Choi, S., Cuny, G. D., Ding, K., Dobson, B. C., Glicksman, M. A., Auerbach, K., and Stein, R. L. (2008) Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors Biochemistry 47, 8367-8377 10.1021/bi800732v
30. Ray, S., Bender, S., Kang, S., Lin, R., Glicksman, M. A., and Liu, M. (2014) The Parkinson Disease-linked LRRK2 Protein Mutation I2020T Stabilizes an Active State Conformation Leading to Increased Kinase Activity J. Biol. Chem. 289, 13042-13053 10.1074/jbc.M113.537811
31. Zhou, T., Commodore, L., Huang, W. S., Wang, Y., Thomas, M., Keats, J., Xu, Q., Rivera, V. M., Shakespeare, W. C., Clackson, T., Dalgarno, D. C., and Zhu, X. (2011) Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance Chem. Biol. Drug Des. 77, 1-11 10.1111/j.1747-0285.2010.01054.x
32. Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J. D., Patricelli, M. P., Nomanbhoy, T. K., Alessi, D. R., and Gray, N. S. (2011) Characterization of a selective inhibitor of the Parkinson?s disease kinase LRRK2 Nat. Chem. Biol. 7, 203-205 10.1038/nchembio.538
33. Ray, S. and Liu, M. (2012) Current understanding of LRRK2 in Parkinson?s disease: biochemical and structural features and inhibitor design Future Med. Chem. 4, 1701-1713 10.4155/fmc.12.110
34. Shelanski, M. L., Gaskin, F., and Cantor, C. R. (1973) Microtubule assembly in the absence of added nucleotides Proc. Natl. Acad. Sci. U. S. A. 70, 765-768 10.1073/pnas.70.3.765
35. Lee, J. C. and Timasheff, S. N. (1977) In vitro reconstitution of calf brain microtubules: effects of solution variables Biochemistry 16, 1754-1764 10.1021/bi00627a037
36. Begley, D. J. (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities Pharmacol. Ther. 104, 29-45 10.1016/j.pharmthera.2004.08.001
37. Hye, A., Lynham, S., Thambisetty, M., Causevic, M., Campbell, J., Byers, H. L., Hooper, C., Rijsdijk, F., Tabrizi, S. J., Banner, S., Shaw, C. E., Foy, C., Poppe, M., Archer, N., Hamilton, G., Powell, J., Brown, R. G., Sham, P., Ward, M., and Lovestone, S. (2006) Proteome-based plasma biomarkers for Alzheimer?s disease Brain 129, 3042-3050 10.1093/brain/awl279
38. Dzamko, N., Chua, G., Ranola, M., Rowe, D. B., and Halliday, G. M. (2013) Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson?s disease patients J. Parkinsons Dis. 3, 145-152 10.3233/JPD-130174
39. Schneider, P., Hampel, H., and Buerger, K. (2009) Biological marker candidates of Alzheimer?s disease in blood, plasma, and serum CNS Neurosci. Ther. 15, 358-374 10.1111/j.1755-5949.2009.00104.x
40. Brighina, L., Prigione, A., Begni, B., Galbussera, A., Andreoni, S., Piolti, R., and Ferrarese, C. (2010) Lymphomonocyte alpha-synuclein levels in aging and in Parkinson disease Neurobiol. Aging 31, 884-885 10.1016/j.neurobiolaging.2008.06.010
41. Nayak, V. J. W. a. R. C. and Nayak, V. J. (2015) Re-circulating Phagocytes Loaded with CNS Debris: A Potential Marker of Neurodegeneration in Parkinson?s Disease? AIMS Med. Sci. 2, 26-34 10.3934/medsci.2015.1.26
42. Kawakami, F., Shimada, N., Ohta, E., Kagiya, G., Kawashima, R., Maekawa, T., Maruyama, H., and Ichikawa, T. (2014) Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3beta FEBS J. 281, 3-13 10.1111/febs.12579
43. Lindwall, G. and Cole, R. D. (1984) Phosphorylation affects the ability of tau protein to promote microtubule assembly J. Biol. Chem. 259, 5301-5305
44. Flaherty, D. B., Soria, J. P., Tomasiewicz, H. G., and Wood, J. G. (2000) Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants J. Neurosci. Res. 62, 463-472 10.1002/1097-4547(20001101)62:3<463::AID-JNR16>3.0.CO;2-7
45. Lin, C. H., Tsai, P. I., Wu, R. M., and Chien, C. T. (2010) LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ss J. Neurosci. 30, 13138-13149 10.1523/JNEUROSCI.1737-10.2010
46. Sheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C. E., Dominguez, S. L., Solanoy, H. O., Drummond, J., Zhang, X., Ding, X., Cai, F., Song, Q., Li, X., Yue, Z., van der Brug, M. P., Burdick, D. J., Gunzner-Toste, J., Chen, H., Liu, X., Estrada, A. A., Sweeney, Z. K., Scearce-Levie, K., Moffat, J. G., Kirkpatrick, D. S., and Zhu, H. (2012) Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations Sci. Transl. Med. 4, 164ra161 10.1126/scitranslmed.3004485
47. Nichols, R. J., Dzamko, N., Morrice, N. A., Campbell, D. G., Deak, M., Ordureau, A., Macartney, T., Tong, Y., Shen, J., Prescott, A. R., and Alessi, D. R. (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson?s disease-associated mutations and regulates cytoplasmic localization Biochem. J. 430, 393-404 10.1042/BJ20100483
48. Liu, M., Kang, S., Ray, S., Jackson, J., Zaitsev, A. D., Gerber, S. A., Cuny, G. D., and Glicksman, M. A. (2011) Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant Biochemistry 50, 9399-9408 10.1021/bi201173d
49. Liu, M., Bender, S. A., Cuny, G. D., Sherman, W., Glicksman, M., and Ray, S. S. (2013) Type II kinase inhibitors show an unexpected inhibition mode against Parkinson?s disease-linked LRRK2 mutant G2019S Biochemistry 52, 1725-1736 10.1021/bi3012077
50. Gilsbach, B. K., Ho, F. Y., Vetter, I. R., van Haastert, P. J., Wittinghofer, A., and Kortholt, A. (2012) Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations Proc. Natl. Acad. Sci. U. S. A. 109, 10322-10327 10.1073/pnas.1203223109
51. Mikhail, F., Calingasan, N., Parolari, L., Subramanian, A., Yang, L., and Flint Beal, M. (2015) Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau Hum. Mol. Genet. 24, 3545-3556 10.1093/hmg/ddv105